drugset / Trial / NCT04699214
Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment
RandomizedParallel-groupSingle-blindTreatment
Summary
To evaluate the effectiveness, safety and tolerability of Endostar (recombinant human endostatin) combined with AI chemotherapy in adjuvant treatment after radical resection of recurrent soft tissue sarcoma.
Timeline
- Start
- 2020-09-01
- Primary completion
- 2023-08-31
- Completion
- 2023-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 45 mg | Intravenous |
| Comparator | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | 400 mg/m2 | — |
| Comparator | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |
| Comparator | Ifosfamide | Small molecule | 2000 mg/m2 | Intravenous |